G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol

被引:41
作者
Qi, Rong [1 ,2 ]
Li, Yan-zhi [1 ,2 ,4 ]
Chen, Cong [1 ,2 ]
Cao, Yi-ni [1 ,2 ]
Yu, Mao-mao [1 ,2 ]
Xu, Lu [1 ,2 ]
He, Bing [3 ]
Jie, Xu [1 ,2 ]
Shen, Wen-wen [1 ,2 ]
Wang, Yu-nan [1 ,2 ]
van Dongen, Mallory A. [5 ]
Liu, Guo-qing [1 ,2 ]
Holl, Mark M. Banaszak [5 ]
Zhang, Qiang [3 ]
Ke, Xue [4 ]
机构
[1] Peking Univ, Hlth Sci Ctr, Inst Cardiovasc Sci, Beijing 100191, Peoples R China
[2] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China
[3] Peking Univ, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
[4] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Jiangsu, Peoples R China
[5] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
基金
中国国家自然科学基金;
关键词
PEG-PAMAM dendrimers; Nanostructured lipid carriers; Probucol; Water solubility; Oral bioavailability; Lipid-lowering effect; SYSTEMS CHI-ADDNSS; DRUG-DELIVERY; HYPERCHOLESTEROLEMIA; TECHNOLOGY; ABSORPTION; LIPOSOMES; TRANSPORT; POLYMERS; RELEASE; MICE;
D O I
10.1016/j.jconrel.2015.05.281
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This work aimed to improve the oral bioavailability and plasma lipid-lowering effect of probucol (PB) by constructing a combined drug delivery system (CDDS) composed of nanostructured lipid carrier (NLC) and PEGylated poly(amidoamine) dendrimer (PEG-PAMAM). PEG-PAMAM with dendrimer generations of 5 (G5PEG) or 7 (G7-PEG) were incorporated in PB-NLCs to form PB-CDDSs, PB-NLCs/G5-PEG and PB-NLCs/G7-PEG. The resultant two kinds of PB-CDDSs were characterized by particle size, zeta potential, drug encapsulation efficacy, PB release rates, and physical stability. Formulation effects of NLC and CDDS on the cellular uptake of hydrophobic drug were explored in Caco-2 cells by fluorescent Cy5 dye as a hydrophobic drug model. Furthermore, in vivo pharmacokinetics of the PB-CDDS composed of G5-PEG and PB-NLCs were investigated in a low density lipoprotein receptor knockout (LDLr-/-) mouse model, including plateau plasma PB concentrations after oral administration of multiple doses, and bioavailability after oral administration of a single dose of different PB formulations. In addition, lipid-lowering effect of PB-NLCs/G5-PEG was studied. The results indicate that both G5-PEG and G7-PEG significantly improved aqueous solubility of PB. The two PB-CDDSs exhibited similar particle size (around 150 nm) as PB-NLCs, but slower PB burst release rate, higher total PB release amount, and better particle morphology and storage stability than PB-NLCs. In comparison with traditional NLC, CDDS dramatically enhanced cellular uptake of Cy5 into Caco-2 cells. In vivo results demonstrate that PB-NLCs/G5-PEG had the highest plateau plasma PB concentration and oral bioavailability, and the greatest cholesterollowering effect in comparison with PB suspensions and PB-NLCs. Therefore, G5-PEG incorporating NLC can be exploited as a promising drug delivery system to improve oral bioavailability and lipid-lowering effect of PB. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:160 / 168
页数:9
相关论文
共 27 条
  • [1] CHARACTERIZATION OF THE CELLULAR REDUCTION OF 3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE (MTT) - SUBCELLULAR-LOCALIZATION, SUBSTRATE DEPENDENCE, AND INVOLVEMENT OF MITOCHONDRIAL ELECTRON-TRANSPORT IN MTT REDUCTION
    BERRIDGE, MV
    TAN, AS
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 303 (02) : 474 - 482
  • [2] PROBUCOL - A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN HYPERCHOLESTEROLEMIA
    BUCKLEY, MMT
    GOA, KL
    PRICE, AH
    BROGDEN, RN
    [J]. DRUGS, 1989, 37 (06) : 761 - 800
  • [3] Incremental replacement of saturated fats by n-3 fatty acids in high-fat, high-cholesterol diets reduces elevated plasma lipid levels and arterial lipoprotein lipase, macrophages and atherosclerosis in LDLR-/- mice
    Chang, Chuchun L.
    Torrejon, Claudia
    Jung, Un Ju
    Graf, Kristin
    Deckelbaum, Richard J.
    [J]. ATHEROSCLEROSIS, 2014, 234 (02) : 401 - 409
  • [4] In Vivo Bioequivalence and In Vitro Similarity Factor (f2) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match?
    Duan, John Z.
    Riviere, Kareen
    Marroum, Patrick
    [J]. PHARMACEUTICAL RESEARCH, 2011, 28 (05) : 1144 - 1156
  • [5] Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
    Esfand, R
    Tomalia, DA
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (08) : 427 - 436
  • [6] New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers
    Gardikis, Konstantinos
    Tsimplouli, Chrisiida
    Dimas, Konstantinos
    Micha-Screttas, Maria
    Demetzos, Costas
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 402 (1-2) : 231 - 237
  • [7] New Drug Delivery Nanosystem Combining Liposomal and Dendrimeric Technology (Liposomal Locked-In Dendrimers) for Cancer Therapy
    Gardikis, Konstantinos
    Hatziantoniou, Sophia
    Bucos, Madalina
    Fessas, Dimitrios
    Signorelli, Marco
    Felekis, Theodoros
    Zervou, Maria
    Screttas, Constantinos G.
    Steele, Barry R.
    Ionov, Maksim
    Micha-Screttas, Maria
    Klajnert, Barbara
    Bryszewska, Maria
    Demetzos, Costas
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (08) : 3561 - 3571
  • [8] Dendrimers and dendritic polymers in drug delivery
    Gillies, ER
    Fréchet, JMJ
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (01) : 35 - 43
  • [9] G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity
    Goldberg, Deborah S.
    Vijayalakshmi, Nirmalkumar
    Swaan, Peter W.
    Ghandehari, Hamidreza
    [J]. JOURNAL OF CONTROLLED RELEASE, 2011, 150 (03) : 318 - 325
  • [10] Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice
    Ishida, E
    Managit, C
    Kawakami, S
    Nishikawa, M
    Yamashita, F
    Hashida, M
    [J]. PHARMACEUTICAL RESEARCH, 2004, 21 (06) : 932 - 939